Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. (original) (raw)

• Journal List
• Proc Natl Acad Sci U S A
• v.82(7); 1985 Apr
• PMC397515

Proc Natl Acad Sci U S A. 1985 Apr; 82(7): 2173–2177.

Abstract

N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces neuropathological and clinical abnormalities in humans, monkeys, and mice that closely resemble idiopathic parkinsonism. N-Methyl-4-phenylpyridine (MPP+), a metabolite of MPTP formed by monoamine oxidase B, is accumulated into striatal and cerebral cortical synaptosomes by the dopamine and norepinephrine uptake systems, respectively, whereas MPTP itself is not accumulated. The potencies of drugs in inhibiting [3H]MPP+ or [3H]dopamine uptake into striatal synaptosomes are very similar, as are potencies in inhibiting [3H]MPP+ or [3H]norepinephrine uptake into cortical synaptosomes. The Km values for [3H]MPP+ uptake are 170 and 65 nM and the Vmax values are 2 and 0.1 nmol/g of tissue per min in rat striatum and cortex, respectively, similar to values for [3H]dopamine uptake, Autoradiography of accumulated [3H]MPP+ in slices of rat brain shows high densities in the caudate-putamen and nucleus accumbens. Furthermore, blockade of dopamine uptake by mazindol prevents MPTP-induced damage to nigrostriatal dopamine neurons, indicating that MPP+ concentration into dopamine neurons explains their selective destruction by MPTP.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

• Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979 Dec;1(3):249–254. [PubMed] [Google Scholar]
• Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983 Feb 25;219(4587):979–980. [PubMed] [Google Scholar]
• Langston JW, Ballard P. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci. 1984 Feb;11(1 Suppl):160–165. [PubMed] [Google Scholar]
• Burns RS, Markey SP, Phillips JM, Chiueh CC. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man. Can J Neurol Sci. 1984 Feb;11(1 Suppl):166–168. [PubMed] [Google Scholar]
• Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A. 1983 Jul;80(14):4546–4550. [PMC free article] [PubMed] [Google Scholar]
• Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 1984 Feb 6;292(2):390–394. [PubMed] [Google Scholar]
• Hallman H, Olson L, Jonsson G. Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. Eur J Pharmacol. 1984 Jan 13;97(1-2):133–136. [PubMed] [Google Scholar]
• Heikkila RE, Hess A, Duvoisin RC. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 1984 Jun 29;224(4656):1451–1453. [PubMed] [Google Scholar]
• Wallace RA, Boldry R, Schmittgen T, Miller D, Uretsky N. Effect of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain & heart. Life Sci. 1984 Jul 16;35(3):285–291. [PubMed] [Google Scholar]
• Sershen H, Reith ME, Hashim A, Lajtha A. Reduction of dopamine uptake and cocaine binding in mouse striatum by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Eur J Pharmacol. 1984 Jun 15;102(1):175–178. [PubMed] [Google Scholar]
• Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature. 1984 Oct 4;311(5985):464–467. [PubMed] [Google Scholar]
• Langston JW, Irwin I, Langston EB, Forno LS. 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett. 1984 Jul 13;48(1):87–92. [PubMed] [Google Scholar]
• Chiba K, Trevor A, Castagnoli N., Jr Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun. 1984 Apr 30;120(2):574–578. [PubMed] [Google Scholar]
• Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 1984 Oct 4;311(5985):467–469. [PubMed] [Google Scholar]
• Langston JW, Irwin I, Langston EB, Forno LS. Pargyline prevents MPTP-induced parkinsonism in primates. Science. 1984 Sep 28;225(4669):1480–1482. [PubMed] [Google Scholar]
• Javitch JA, Uhl GR, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain. Proc Natl Acad Sci U S A. 1984 Jul;81(14):4591–4595. [PMC free article] [PubMed] [Google Scholar]
• Chiueh CC, Markey SP, Burns RS, Johannessen JN, Pert A, Kopin IJ. Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur J Pharmacol. 1984 Apr 20;100(2):189–194. [PubMed] [Google Scholar]
• Boyce S, Kelly E, Reavill C, Jenner P, Marsden CD. Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. Biochem Pharmacol. 1984 Jun 1;33(11):1747–1752. [PubMed] [Google Scholar]
• Sahgal A, Andrews JS, Biggins JA, Candy JM, Edwardson JA, Keith AB, Turner JD, Wright C. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects locomotor activity without producing a nigrostriatal lesion in the rat. Neurosci Lett. 1984 Jul 27;48(2):179–184. [PubMed] [Google Scholar]
• Wieczorek CM, Parsons B, Rainbow TC. Quantitative autoradiography of [3H]MPTP binding sites in rat brain. Eur J Pharmacol. 1984 Mar 2;98(3-4):453–454. [PubMed] [Google Scholar]
• Parsons B, Rainbow TC. High-affinity binding sites for [3H]MPTP may correspond to monamine oxidase. Eur J Pharmacol. 1984 Jul 13;102(2):375–377. [PubMed] [Google Scholar]
• Levitt P, Pintar JE, Breakefield XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci U S A. 1982 Oct;79(20):6385–6389. [PMC free article] [PubMed] [Google Scholar]
• Pintar JE, Levitt P, Salach JI, Weyler W, Rosenberg MB, Breakefield XO. Specificity of antisera prepared against pure bovine MAO-B. Brain Res. 1983 Oct 3;276(1):127–139. [PubMed] [Google Scholar]
• Trifiletti RR, Snowman AM, Snyder SH. Barbiturate recognition site on the GABA/benzodiazepine receptor complex is distinct from the picrotoxinin/TBPS recognition site. Eur J Pharmacol. 1984 Nov 13;106(2):441–447. [PubMed] [Google Scholar]
• McPherson GA. A practical computer-based approach to the analysis of radioligand binding experiments. Comput Programs Biomed. 1983 Aug-Oct;17(1-2):107–113. [PubMed] [Google Scholar]
• Unnerstall JR, Niehoff DL, Kuhar MJ, Palacios JM. Quantitative receptor autoradiography using [3H]ultrofilm: application to multiple benzodiazepine receptors. J Neurosci Methods. 1982 Jul;6(1-2):59–73. [PubMed] [Google Scholar]
• Javitch JA, Blaustein RO, Snyder SH. [3H]mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. Mol Pharmacol. 1984 Jul;26(1):35–44. [PubMed] [Google Scholar]
• LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
• Hyttel J. Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(3):277–295. [PubMed] [Google Scholar]
• Lee CM, Javitch JA, Snyder SH. Characterization of [3H]desipramine binding associated with neuronal norepinephrine uptake sites in rat brain membranes. J Neurosci. 1982 Oct;2(10):1515–1525. [PMC free article] [PubMed] [Google Scholar]
• Wong DT, Molloy BB, Bymaster FP. Blockade of monoamine uptake by 1-amino-4-phenylbicyclo(2,2,2)octane (EXP 561) in rat brain and heart. Neuropharmacology. 1977 Jan;16(1):11–15. [PubMed] [Google Scholar]
• Hamberger B, Masuoka D. Localization of catecholamine uptake in rat brain slices. Acta Pharmacol Toxicol (Copenh) 1965;22(4):363–368. [PubMed] [Google Scholar]
• Lewin R. Brain enzyme is the target of drug toxin. Science. 1984 Sep 28;225(4669):1460–1462. [PubMed] [Google Scholar]
• Palacios JM, Wiederhold KH. Acute administration of 1-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a compound producing parkinsonism in humans, stimulates [2-14C]deoxyglucose uptake in the regions of the catecholaminergic cell bodies in the rat and guinea pig brains. Brain Res. 1984 May 28;301(1):187–191. [PubMed] [Google Scholar]
• GREENFIELD JG, BOSANQUET FD. The brain-stem lesions in Parkinsonism. J Neurol Neurosurg Psychiatry. 1953 Nov;16(4):213–226. [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences